More than two billion people worldwide lack access to basic medicines. With the frequency and duration of drug shortages rapidly increasing, transforming pharmaceutical supply chains is more important than ever. Biomanufacturing can solve these challenges and enable efficient, controlled, and cost-effective production of essential medicines, reducing global reliance on inadequate, legacy supply chains. Over the past year, Antheia has repeatedly demonstrated the success of its platform technology and biomanufacturing processes at a commercial scale of 116,000L and is actively bringing its first products to market. Join this talk to hear how the company has rapidly scaled some of the most complex small molecule drugs from lab to commercial scale.